Data patterns are predictors of glaucoma medication use

Article

Research investigating the epidemiology of IOP-lowering medication use in the U.S. population will hopefully suggest targets for efforts designed to improve medication access and patient care, one expert says.

Boston-Research investigating the epidemiology of IOP-lowering medication use in the U.S. population will hopefully suggest targets for efforts designed to improve medication access and patient care, said Mark Swanson, OD, MSPH, at the annual meeting of the American Academy of Optometry.

The study analyzed pooled data from two capture periods (2005-2006 and 2007- 2008) of the National Health and Nutrition Examination Survey (NHANES). The database was searched for ophthalmic drugs used for IOP-lowering. Estimates of distribution were calculated for glaucoma drug usage and medication type across various sociodemographic subgroups, and multivariate regression analyses were conducted to identify associations between sociodemographic variables and glaucoma medication use.

NHANES study data

Based on the NHANES methodology, its database is considered a good resource for estimating usage of IOP-lowering medications in the population and sociodemographic variables associated with its use. However, Dr. Swanson acknowledged there are some limitations.

Results of the multivariate model showed the likelihood of glaucoma medication use increased with increasing age and was significantly greater among African-Americans compared with whites, while individuals at the near poverty level were significantly less likely to be using medications for IOP-lowering compared with a reference group in the highest income category, reported Dr. Swanson, associate professor of optometry, and chief, ocular disease service, School of Optometry, University of Alabama at Birmingham.

Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
© 2025 MJH Life Sciences

All rights reserved.